firibastat: Clinical Trials

5 trials of firibastat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 2 Phase 1, 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 32Completed 1, Terminated 1
Phase 21Completed 1

Follow firibastat: new trials by email Literature Review of firibastat trials Research Report on firibastat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
Firibastat (QGC001) Period 1 - Hypertension (HTN)
Phase 3TerminatedQuantum Genomics SA4192021-08-052023-01-17
Firibastat in Treatment-resistant Hypertension
Firibastat, Placebo - Hypertension
Phase 3CompletedQuantum Genomics SA5152020-06-252022-10-20
Pharmacokinetics in End Stage Renal Disease Patients
firibastat - Healthy Volunteers, Renal Failure
Phase 1CompletedQuantum Genomics SA282019-09-172021-03-10
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Ramipril, Firibastat - Myocardial Infarction
Phase 2CompletedQuantum Genomics SA2952019-06-042023-02-27
Evaluation of the PK Profile of Firibastat Following Administration of Firibastat Prototype Tablet Formulations
Firibastat - Healthy Males
Phase 1CompletedQuantum Genomics SA122019-02-152019-06-18

Conditions studied

Hypertension (2)  ·  Myocardial Infarction (1)  ·  Renal Insufficiency (1)

Sponsors

Quantum Genomics SA (5)

Countries

France (3)  ·  Germany (2)  ·  Poland (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Canada (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Slovakia (1)

Top investigators

George Bakris, MD (1)  ·  Gilles Montalescot, MD, PhD (1)

Results publications

PMID 33027067, PMID 36757536

NIH funding

2018 (1), 2019 (1)